How Ipamorelin Works in the Research

Start here

If you have searched what does ipamorelin peptide do, here is the plain answer. Ipamorelin flips one switch. The switch is a receptor called GHS-R1a — the same one the hunger hormone ghrelin uses. When ipamorelin binds it on the pituitary gland (a small gland under the brain), the gland releases a short burst of growth hormone (GH), the body's repair-and-growth signal.

The trick is that it only flips that one switch hard. Older peptides like it also nudged up cortisol (a stress hormone) and prolactin. Ipamorelin, in the studies, leaves those two alone ^[1]. So you get the growth-hormone burst without the stress-hormone side trip. That is what "selective" means here.

The burst is brief — it peaks about 40 minutes after a dose and is gone within hours ^[2]. The body's own rhythm stays in charge. Below, the receptor logic in full.

The receptor logic

GHS-R1a is the ghrelin / growth hormone secretagogue receptor. It sits on pituitary somatotrophs — the GH-secreting cells. Ipamorelin is a ghrelin mimetic: it binds where ghrelin binds and triggers the same Gq/phospholipase-C cascade, raising intracellular calcium and driving GH out of the cell ^[1].

This is a different door than growth-hormone-releasing hormone (GHRH) uses. GHRH works through a cyclic-AMP pathway on a different receptor. Two doors, two cascades, one shared output: GH. That separation is the entire rationale for pairing a ghrelin-receptor agonist with a GHRH analog — they push the same pulse through independent mechanisms.

The pulse is self-limiting. Ipamorelin amplifies the body's own GH rhythm rather than flooding the system with a flat, constant signal.

Why selectivity is the headline

In the 1998 founding study, ipamorelin released GH about as potently as GHRP-6 — swine ED50 of 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6 — yet it did not raise ACTH or cortisol above the GHRH baseline, even at doses more than 200-fold over the GH ED50 ^[1]. Prolactin was unaffected.

That is unusual. GHRP-6 and GHRP-2 carry adrenocortical and prolactin stimulation as part of the package. Ipamorelin separated the GH signal from those off-target hormones. The study titled it accordingly: the first selective growth hormone secretagogue ^[1].

The selectivity even survives a glucocorticoid load. Methylprednisolone (5.0 mg/kg/day, 8 days) did not blunt the acute GH response to ipamorelin in rats, and the combination raised IGF-1 and improved body-weight recovery versus steroid alone ^[11]. The GH door stays open under steroid pressure.

Ipamorelin vs sermorelin

These act on different receptors. Sermorelin is a GHRH analog — it mimics growth-hormone-releasing hormone and works through the GHRH receptor's cyclic-AMP pathway. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist ^[1]. Sermorelin and ipamorelin are not interchangeable; they are complementary doors to the same GH pulse, which is why GHRH analogs and ghrelin mimetics are studied together rather than against each other. Sermorelin's GHRH lineage is the same family as CJC-1295 and tesamorelin.

Ipamorelin vs tesamorelin

Tesamorelin, like sermorelin, is a GHRH analog acting on the GHRH receptor — and it is the one compound in this comparison set with a real approved human indication (its label and approval are not the subject of this digest). Ipamorelin is mechanistically distinct: a ghrelin / GHS-R1a agonist ^[1], never approved for any indication ^[3]. The contrast that matters is receptor identity — GHRH-receptor (tesamorelin) versus ghrelin-receptor (ipamorelin) — and the evidence base: tesamorelin reached approval; ipamorelin's only Phase 2 efficacy trial failed ^[3].

The peripheral side-channels

GHS-R1a is not only on the pituitary. The receptor, and ipamorelin's reach, extend to the gut and the pancreas — which is where the "does it make you hungry" question comes from.

Growth-hormone-releasing peptides partly act by triggering the body's own ghrelin: GHRP-class compounds accumulate in the gastric mucosa, and gastric resection cut GHRP-6-induced GH release by 60–70% ^[9]. Acute central administration of ghrelin and GH secretagogues activates hypothalamic appetite centers and induces feeding in rats — a class-level orexigenic signal ^[10].

There is also a metabolic side-channel: ipamorelin directly evoked insulin release from rat pancreatic tissue (10^-12 to 10^-6 M), a GH-independent effect blocked by L-type calcium-channel and adrenergic/cholinergic antagonism ^[13]. Selectivity is for the stress hormones — not for every downstream system the ghrelin receptor touches.